• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

银屑病流行病学筛查工具(PEST):来自 GRAPPA2009 年会的报告。

Psoriasis Epidemiology Screening Tool (PEST): a report from the GRAPPA 2009 annual meeting.

机构信息

University of Leeds, Chapel Allerton Hospital, Leeds, LS7 4SA, UK.

出版信息

J Rheumatol. 2011 Mar;38(3):551-2. doi: 10.3899/jrheum.101119.

DOI:10.3899/jrheum.101119
PMID:21362785
Abstract

Patients with psoriasis attending general practitioner and dermatology clinics may complain about their joints, but it may be difficult for the nonrheumatologist to distinguish psoriatic arthritis (PsA) from other forms of arthritis. A screening tool for PsA would therefore be useful to both general practitioners and dermatologists and help identify patients for further evaluation by a rheumatologist. Although several screening tools have been developed, the Psoriasis Epidemiology Screening Tool (PEST) has the advantage of simplicity and ease of use. This new instrument consists of 5 simple questions supported by the addition of a manikin for patient markup. During development, the questionnaire has shown a sensitivity of 0.94 and a specificity of 0.78. Further validation of this and the other questionnaires is now required. A "head to head" study of the PEST, ToPAS (Toronto Psoriatic Arthritis Screening questionnaire), and PASE (Psoriatic Arthritis Screening and Evaluation) tools is planned in a secondary-care population with psoriasis. This study is important not only to confirm the comparative performance of the instruments, but also to confirm the high figures for sensitivity in a secondary-care population.

摘要

就诊于普通科医生和皮肤科诊所的银屑病患者可能会抱怨关节问题,但非风湿病专家可能难以将银屑病关节炎(PsA)与其他类型的关节炎区分开来。因此,一种用于筛查 PsA 的工具对普通科医生和皮肤科医生都很有用,并有助于将患者识别出来以供风湿病专家进一步评估。尽管已经开发出了几种筛查工具,但银屑病流行病学筛查工具(PEST)具有简单易用的优点。这种新工具由 5 个简单的问题组成,并附有一个患者标记的人体模型。在开发过程中,该问卷的敏感性为 0.94,特异性为 0.78。现在需要对该问卷和其他问卷进行进一步验证。计划在二级保健人群中进行 PEST、ToPAS(多伦多银屑病关节炎筛查问卷)和 PASE(银屑病关节炎筛查和评估)工具的“面对面”研究。这项研究不仅对于确认这些工具的比较性能很重要,而且对于确认二级保健人群中高敏感性数字也很重要。

相似文献

1
Psoriasis Epidemiology Screening Tool (PEST): a report from the GRAPPA 2009 annual meeting.银屑病流行病学筛查工具(PEST):来自 GRAPPA2009 年会的报告。
J Rheumatol. 2011 Mar;38(3):551-2. doi: 10.3899/jrheum.101119.
2
Toronto Psoriatic Arthritis Screening (ToPAS) questionnaire: a report from the GRAPPA 2009 annual meeting.多伦多银屑病关节炎筛查(ToPAS)问卷:GRAPPA 2009 年会报告。
J Rheumatol. 2011 Mar;38(3):546-7. doi: 10.3899/jrheum.101117.
3
Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics.银屑病关节炎筛查工具在欧洲/北美皮肤科诊所银屑病患者中的比较性能。
J Am Acad Dermatol. 2014 Oct;71(4):649-55. doi: 10.1016/j.jaad.2014.05.010. Epub 2014 Jun 25.
4
Psoriatic Arthritis Screening and Evaluation (PASE) questionnaire and the role of dermatologists: a report from the GRAPPA 2009 annual meeting.银屑病关节炎筛查和评估(PASE)问卷和皮肤科医生的作用:来自 GRAPPA 2009 年会的报告。
J Rheumatol. 2011 Mar;38(3):548-50. doi: 10.3899/jrheum.101118.
5
The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool.PASE问卷:银屑病关节炎筛查与评估工具的预试验
J Am Acad Dermatol. 2007 Oct;57(4):581-7. doi: 10.1016/j.jaad.2007.04.001. Epub 2007 Jul 3.
6
Dermatology screening tools: project update from the GRAPPA 2012 annual meeting.皮肤病学筛查工具:GRAPPA2012 年会项目进展。
J Rheumatol. 2013 Aug;40(8):1425-7. doi: 10.3899/jrheum.130455.
7
Prologue: 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).序言:2009 年银屑病和银屑病关节炎研究与评估团体(GRAPPA)。
J Rheumatol. 2011 Mar;38(3):522-5. doi: 10.3899/jrheum.101113.
8
Prologue: 2012 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).序言:2012 年银屑病和银屑病关节炎研究和评估团体(GRAPPA)年会。
J Rheumatol. 2013 Aug;40(8):1407-9. doi: 10.3899/jrheum.130450.
9
High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires.在银屑病治疗效果不佳的重度银屑病患者中,存在较高比例的银屑病关节炎。
Ann Rheum Dis. 2013 May;72(5):736-40. doi: 10.1136/annrheumdis-2012-201706. Epub 2012 Jun 23.
10
Evaluation of an existing screening tool for psoriatic arthritis in people with psoriasis and the development of a new instrument: the Psoriasis Epidemiology Screening Tool (PEST) questionnaire.对一种用于银屑病患者的银屑病关节炎现有筛查工具的评估以及一种新工具的开发:银屑病流行病学筛查工具(PEST)问卷。
Clin Exp Rheumatol. 2009 May-Jun;27(3):469-74.

引用本文的文献

1
Psoriasis.银屑病
Nat Rev Dis Primers. 2025 Jun 26;11(1):45. doi: 10.1038/s41572-025-00630-5.
2
The Romanian Translation and Cultural Adaptation of the Early Arthritis for Psoriatic Patients (EARP) Questionnaire, Psoriasis Epidemiology Screening Tool (PEST), and Toronto Psoriatic Arthritis Screen 2 (ToPAS 2).银屑病患者早期关节炎(EARP)问卷、银屑病流行病学筛查工具(PEST)和多伦多银屑病关节炎筛查2(ToPAS 2)的罗马尼亚语翻译及文化调适
Clin Pract. 2024 Oct 16;14(5):2125-2138. doi: 10.3390/clinpract14050168.
3
Subclinical psoriatic arthritis and disease interception-where are we in 2024?
亚临床银屑病关节炎与疾病干预——2024年我们处于什么阶段?
Rheumatology (Oxford). 2025 Jan 1;64(1):56-64. doi: 10.1093/rheumatology/keae399.
4
Rheuma-VOR study: optimising healthcare of rheumatic diseases by multiprofessional coordinating centres.Rheuma-VOR 研究:通过多专业协调中心优化风湿性疾病的医疗保健。
Ann Rheum Dis. 2024 Jan 11;83(2):184-193. doi: 10.1136/ard-2023-224205.
5
Efficacy of guselkumab, a selective IL-23 inhibitor, in Preventing Arthritis in a Multicentre Psoriasis At-Risk cohort (PAMPA): protocol of a randomised, double-blind, placebo controlled multicentre trial.选择性白细胞介素-23抑制剂古塞库单抗在预防多中心银屑病高危队列(PAMPA)关节炎中的疗效:一项随机、双盲、安慰剂对照多中心试验方案
BMJ Open. 2022 Dec 23;12(12):e063650. doi: 10.1136/bmjopen-2022-063650.
6
Multidisciplinary Rheuma-Derma Clinics: 5 Years of Experience at the San Marco Hospital in Catania.多学科风湿皮肤病诊所:卡塔尼亚圣马尔科医院五年经验
Dermatol Ther (Heidelb). 2022 Dec;12(12):2829-2837. doi: 10.1007/s13555-022-00837-4. Epub 2022 Nov 4.
7
Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry.在CorEvitas银屑病登记处中接受司库奇尤单抗和其他生物制剂治疗的司库奇尤单抗患者的治疗结果。
Dermatol Ther (Heidelb). 2022 Dec;12(12):2797-2815. doi: 10.1007/s13555-022-00834-7. Epub 2022 Nov 4.
8
Utilization of the Psoriasis Epidemiology Screening Tool (PEST): A Risk Stratification Strategy for Early Referral of Psoriatic Arthritis Patients to Minimize Irreversible Erosive Joint Damage.利用银屑病流行病学筛查工具(PEST):一种对银屑病关节炎患者进行早期转诊的风险分层策略,以最大限度地减少不可逆转的侵蚀性关节损伤。
J Cutan Med Surg. 2022 Nov-Dec;26(6):600-603. doi: 10.1177/12034754221128796. Epub 2022 Oct 9.
9
Psoriatic arthritis: prospects for the future.银屑病关节炎:未来展望
Ther Adv Musculoskelet Dis. 2022 Mar 28;14:1759720X221086710. doi: 10.1177/1759720X221086710. eCollection 2022.
10
Psoriasis epidemiology screening tool (PEST) is useful for the detection of psoriatic arthritis in the Japanese population.银屑病流行病学筛查工具(PEST)可用于日本人群中银屑病关节炎的检测。
Sci Rep. 2021 Aug 9;11(1):16146. doi: 10.1038/s41598-021-95620-4.